Previous close | 33.50 |
Open | 33.33 |
Bid | 33.57 x 100 |
Ask | 34.30 x 100 |
Day's range | 32.27 - 33.89 |
52-week range | 3.03 - 49.87 |
Volume | |
Avg. volume | 457,945 |
Market cap | 354.408M |
Beta (5Y monthly) | 2.47 |
PE ratio (TTM) | N/A |
EPS (TTM) | -10.31 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 55.00 |
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002)
Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC’s Phase 1 China study indicates differentiation from PADCEV NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002),
Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study on track to commence in Summer of 2024Pre-clinical data for CRB-913 presented at Obesity Week; IND filing on track by the end of 2024$127M of cash & investments at February 2, 2024; 3+ years of projected runway through Q1 2027Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., March